Nelson Scott M, Shaw Martin, Ewing Benjamin J, McLean Kate, Vechery Afton, Briggs Sharon F
School of Medicine, University of Glasgow, Glasgow, United Kingdom.
Department of Medical Physics, National Health Service Greater Glasgow and Clyde, Glasgow, Scotland, United Kingdom.
Fertil Steril. 2024 Dec;122(6):1114-1123. doi: 10.1016/j.fertnstert.2024.06.024. Epub 2024 Jul 2.
To study the association between antimüllerian hormone (AMH) levels and time of pregnancy. Although it has been hypothesized that serum AMH levels may indicate the chance of conception, findings have been mixed. Given that any association is expected to be modest, and it is possible that previous studies have been underpowered, we investigated this relationship in the largest prospective cohort to date.
Prospective time-to-pregnancy cohort study.
Community.
PATIENT(S): A total of 3,150 US women who had been trying to conceive for <3 months and had purchased a Modern Fertility hormone test.
INTERVENTION(S): We developed a discrete time-to-event model using a binomial complementary log-log error structure within a generalized additive modeling framework, adjusting for confounding factors such as age, body mass index, parity, smoking status, polycystic ovary syndrome, and others. Sensitivity analyses were performed in women with regular menstrual cycles (21-35 days), who did not report using fertility treatments, using alternate AMH level categories (<0.7, 0.7-8.5, >8.5 ng/mL), and AMH levels as a continuous measure.
MAIN OUTCOME MEASURE(S): Primary outcomes included cumulative conception probability within 12 cycles and relative fecundability per menstrual cycle. Conception was defined by a self-reported positive pregnancy test.
RESULT(S): Participants contributed 7.21 ± 5.32 cycles, with 1,325 (42.1%) achieving a pregnancy. Women with low AMH levels (<1 ng/mL, n = 427) had a lower chance of natural conception (adjusted hazard ratio [adjHR], 0.77; 95% confidence interval [CI], 0.64-0.94) compared with women with normal AMH levels (1-5.5 ng/mL). There was no difference between high (5.5+ ng/mL) and normal AMH level categories (adjHR, 1.11; 95% CI, 0.94-1.31). The inclusion of AMH improved the model (net reclassification index 0.10 [0.06-0.14]). The instantaneous probability of conception was highest in cycle four across all AMH categories: the probability of natural conception was 11.2% (95% CI, 9.0-14.0) for low AMH levels, 14.3% (95% CI, 12.3-16.5) for normal AMH levels, and 15.7% (95% CI, 12.9-19.0) for high AMH levels. In the regular cycles sensitivity analysis (n = 1,791), the low AMH group had a lower chance of conception (adjHR, 0.77; 95% CI, 0.61-0.97) in the low AMH group compared with normal AMH, and similarly in the continuous model (adjHR, 0.90; 95% CI, 0.85-0.95).
CONCLUSION(S): Low AMH levels (<1 ng/mL) are independently associated with a modest but significant reduction in the chance of conception.
研究抗苗勒管激素(AMH)水平与怀孕时间之间的关联。尽管有假设认为血清AMH水平可能表明受孕几率,但研究结果不一。鉴于任何关联预计都较为微弱,且之前的研究可能样本量不足,我们在迄今为止最大的前瞻性队列中研究了这种关系。
前瞻性受孕时间队列研究。
社区。
共有3150名美国女性,她们尝试受孕时间小于3个月且购买了现代生育激素检测。
我们在广义相加模型框架内使用二项互补对数-对数误差结构开发了一个离散事件时间模型,对年龄、体重指数、产次、吸烟状况、多囊卵巢综合征等混杂因素进行了调整。在月经周期规律(21 - 35天)、未报告使用生育治疗的女性中进行敏感性分析,使用不同的AMH水平类别(<0.7、0.7 - 8.5、>8.5 ng/mL),并将AMH水平作为连续变量进行分析。
主要结局包括12个周期内的累积受孕概率和每个月经周期的相对受孕能力。受孕通过自我报告的阳性妊娠试验来定义。
参与者贡献了7.21±5.32个周期,其中1325人(42.1%)成功怀孕。与AMH水平正常(1 - 5.5 ng/mL)的女性相比,AMH水平低(<1 ng/mL,n = 427)的女性自然受孕几率较低(调整后风险比[adjHR],0.77;95%置信区间[CI],0.64 - 0.94)。AMH水平高(5.5+ ng/mL)与正常AMH水平类别之间无差异(adjHR,1.11;95% CI,0.94 - 1.31)。纳入AMH改善了模型(净重新分类指数0.10 [0.06 - 0.14])。在所有AMH类别中,受孕的瞬时概率在第4个周期最高:AMH水平低的自然受孕概率为11.2%(95% CI,9.0 - 14.0),AMH水平正常的为14.3%(95% CI,12.3 - 16.5),AMH水平高的为15.7%(95% CI,12.9 - 19.0)。在规律周期敏感性分析(n = 1791)中,与AMH水平正常的女性相比,AMH水平低的组受孕几率较低(adjHR,0.77;95% CI,0.61 - 0.97),在连续模型中情况类似(adjHR,0.90;95% CI,0.85 - 0.95)。
AMH水平低(<1 ng/mL)与受孕几率适度但显著降低独立相关。